CTOs on the Move

Neomorph

www.neomorph.com

 
Neomorph is a venture backed biotechnology company based in San Diego, California.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Neomorph raised $109M on 12/22/2020

Similar Companies

AMIGENICS

AMIGENICS is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

13Therapeutics Inc

13Therapeutics Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Michael

Michael is a Franklinton, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Project Farma (PF)

Project Farma is a patient-focused global leader in advancing technical operations from ideation through commercialization with a proven track record of planning, building, and maintaining manufacturing facilities, capital expansions, and technical operations for complex biologics and novel modalities. We provide end-to-end services for the entire manufacturing lifecycle for pharmaceutical and biotech companies, universities, hospitals, and government agencies. Project Farma has executed 100+ facility builds, retrofits and expansions, managed 400+ large scale capital projects, industrialized 10+ commercial cell, gene, and novel therapies, and managed $6B+ in technical operations capital investments. One of our core values is giving back. Volunteering at hospitals, supporting life science related fundraisers and partnering with nonprofit organizations is an integral part of our culture. In doing so, not only do we raise awareness of many life-threatening diseases, but we also bring our team and our clients team closer to the actual patients and families that will be impacted by our work. Project Farma is a PerkinElmer company. (https://www.projectfarma.com/)

Effector

Effector Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby information in genetic sequences is used to direct synthesis of proteins. Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses. In cancer, the tightly controlled translation of specific proteins becomes dysregulated, leading to malignancy characterized by uncontrolled growth, immune evasion and metastases. eFFECTOR believes that its therapeutic approach can restore the translational control of processes which tumors have hijacked for their benefit, while preserving normal cell function.